Low TYROBP expression predicts poor prognosis in multiple myeloma
Cancer Cell International,
Abstract Background Multiple myeloma (MM) is the second most common refractory hematologic cancer.
Abstract Background Multiple myeloma (MM) is the second most common refractory hematologic cancer.
Haure-Mirande JV, Audrain M, Ehrlich ME, Gandy S. Mol Neurodegener. 2022 Aug 24;17(1):55.